Program
Edaravone
Also written as “MT-1186”, “MCI-186” and “Continuous infusion high-dose MCI-186”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Ischemic Stroke · Cerebral Infarction · Renal Insufficiency · Ischemia, led by 4 companies.
Drug pageEdaravone: every studyAll 38 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shionogiits history only | 230 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since Jul 16, 2025 | Jul 16, 2025 | none ahead |
| Nanjing Yoko Biomedicalits history only | 10 open or running | phase 1since Dec 17, 2019 | Dec 17, 2019 | none ahead |
| Shanghai Auzone Biological Technology | 10 open or running | phase 1since Oct 16, 2023 | Oct 16, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Shanghai Auzone Biological Technology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 16, 2023First study: phase 1 study in Healthy Adult SubjectsFirst studyNCT06107205 · 29 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Shanghai Auzone Biological Technology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06107205Healthy Adult Subjects · United States | 1 | Completed | Dec 14, 2023 | 29 |
How it is read
Names in the registry
- “MT-1186”, 12 entries
- “MCI-186”, 10 entries
- “Edaravone”, 1 entry
- “Continuous infusion high-dose MCI-186”, 1 entry
- “Continuous infusion low-dose MCI-186”, 1 entry
Codes read as this program: MT1186, MCI186.
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 5 studies
- Ischemic Stroke, 2 studies
- Cerebral Infarction, 1 study
- Renal Insufficiency, 1 study
- Ischemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.